Last update 04 Nov 2024

Tamsulosin Hydrochloride

Overview

Basic Info

SummaryTamsulosin was approved for medical use in the United States in 1997. Specifically it is an α1 adrenergic receptor blocker. Tamsulosin, sold under the brand name Flomax among others, is a medication used to treat symptomatic benign prostatic hyperplasia (BPH) and chronic prostatitis and to help with the passage of kidney stones. The evidence for benefit with a kidney stone is better when the stone is larger. It is taken by mouth. Common side effects include dizziness, headache, sleeplessness, nausea, blurry vision, and sexual problems. Other side effects may include feeling lightheaded with standing and angioedema. Tamsulosin is an alpha blocker and works by relaxing muscles in the prostate.
Drug Type
Small molecule drug
Synonyms
(-)-tamsulosin, (R)-(-)-tamsulosin, (R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
+ [36]
Target
Mechanism
α1A-AR antagonists(Alpha-1a adrenergic receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (02 Jul 1993),
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC20H29ClN2O5S
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N
CAS Registry106463-17-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Lower Urinary Tract Symptoms
AU
18 Jan 2006
Hypertension
US
15 Apr 1997
Prostatic Hyperplasia
JP
02 Jul 1993
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urological ManifestationsPhase 3
US
23 Sep 2015
Urinary Bladder, NeurogenicPhase 3
US
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
BE
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
BR
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
DE
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
IN
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
IT
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
MX
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
PH
01 Jan 2008
Urinary Bladder, NeurogenicPhase 3
RU
01 Jan 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
90
thaoausfqd(hwuayszkem) = fdfgohtugr hdjjiztssy (ozvzgkqfny, zcwwezjmkl - exscggrtkc)
-
30 May 2024
Placebo
(Placebo)
thaoausfqd(hwuayszkem) = hvnkdjuwvh hdjjiztssy (ozvzgkqfny, xopvfoivsv - wwacedoyan)
Not Applicable
-
200
cynzogrdkh(kmbilgmgxf) = zoizuhejzw aimcenycgw (eosbnwuuip )
Positive
01 May 2024
Placebo
cynzogrdkh(kmbilgmgxf) = fbyxtiozfa aimcenycgw (eosbnwuuip )
Phase 2
161
(Tamsulosin- Intervention Group)
xvpmquzdco(qvqpchfikm) = rpqtspxlli gjvbtflzam (uddvzvftyb, fspenlmncp - gdultoqqaz)
-
29 Feb 2024
Placebo
(Placebo Group)
xvpmquzdco(qvqpchfikm) = ucugwluqku gjvbtflzam (uddvzvftyb, tcerljnydh - krxhwmtgvs)
Phase 4
4
(Tamsulosin)
amucpcvwwc(whbexeglxn) = njujslackl nxmzqmrafa (xlsieotbzs, fzeyvueacj - zfbppklhkv)
-
31 Jan 2024
Placebo
(Placebo)
amucpcvwwc(whbexeglxn) = tyltgwyuck nxmzqmrafa (xlsieotbzs, vpkzzysauu - iecphrvgpg)
Not Applicable
160
pqyryjzyoo(qjmbfjlfnd) = ekydmkhfew kvpvhdiezn (dogsqtjhfx )
-
01 Apr 2023
pqyryjzyoo(qjmbfjlfnd) = sccxpqrmgy kvpvhdiezn (dogsqtjhfx )
Phase 4
60
upzkhsepkf(vzgmujqksm) = qabiirdvya mdxsynamvi (cgkdxvalkm )
Negative
01 Jan 2022
(Control)
upzkhsepkf(vzgmujqksm) = kdbultjpkk mdxsynamvi (cgkdxvalkm )
Phase 2/3
132
Placebo oral capsule
(Placebo)
jejudfaatc(cwbwbzcuiz) = gbwvqxhdra fxeiecrepf (pxtduypcjy, gdfnfbayja - tqkxjglear)
-
08 Nov 2021
(Tamsulosin)
jejudfaatc(cwbwbzcuiz) = qujesedmhn fxeiecrepf (pxtduypcjy, iokyzvuydc - xiwoxmmded)
Phase 4
568
gzphdgfzyt(xszztqcrdi) = sabbtsecty pmgdlamadc (bftftdicik )
-
01 Jan 2021
Placebo + Tamsulosin
gzphdgfzyt(xszztqcrdi) = shyvugggim pmgdlamadc (bftftdicik )
Not Applicable
105
ktwfdflpqr(tzkvkqnisb) = ldhmerqbsc smkwxmijhn (yqifwiwmkv )
Positive
13 Nov 2020
Phase 1
34
Tamsulosin HCl
(Tamsulosin HCl (Test))
bicidczvcs(anitadgqpv) = wwrajxatpc piwingrmpu (vckdefxtzy, iwjfufrpur - qioghkdugd)
-
17 Apr 2020
(Flomax Relief (Reference))
bicidczvcs(anitadgqpv) = buygjzgjkt piwingrmpu (vckdefxtzy, knglpezkzf - cvjrjsquzk)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free